RT Journal Article
SR Electronic
T1 Presurgical Pazopanib Improves Surgical Outcomes for Renal Cell Carcinoma With High-level IVC Tumor Thrombosis
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 2013
OP 2019
DO 10.21873/invivo.11698
VO 33
IS 6
A1 YASUYOSHI OKAMURA
A1 TOMOAKI TERAKAWA
A1 MARIKO SAKAMOTO
A1 YUKARI BANDO
A1 KOTARO SUZUKI
A1 TAKUTO HARA
A1 JUNYA FURUKAWA
A1 KENICHI HARADA
A1 NOBUYUKI HINATA
A1 YUZO NAKANO
A1 MASATO FUJISAWA
YR 2019
UL http://iv.iiarjournals.org/content/33/6/2013.abstract
AB Background/ Aim: We evaluated surgical outcomes following nephrectomy and thrombectomy with and without presurgical treatment with pazopanib in patients with advanced renal cell carcinoma with inferior vena caval tumor thrombosis. Materials and Methods: We compared surgical outcomes between patients undergoing presurgical treatment with pazopanib vs. surgery-alone in 19 patients who underwent surgery for advanced renal cell carcinoma with high-level inferior vena caval tumor thrombosis at the Kobe University Hospital. Results: Comparing the presurgical group with the surgery-alone group, respectively, the average operative time was 497 min vs. 627 min (p=0.08); average blood loss was 1,928 ml vs. 7,393 ml (p<0.05); average postoperative hospitalization duration was 15.3 days vs. 21.6 days (p=0.05); and the perioperative complication rate was lower (presurgical: 33% vs. surgery-alone: 50%). Conclusion: Presurgical treatment with pazopanib decreased surgical difficulty and improved surgical outcomes for advanced renal cell carcinoma with high-level inferior vena caval tumor thrombosis.